Aspen Aerogels (ASPN) Projected to Post Earnings on Thursday

Aspen Aerogels (NYSE:ASPN) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Aspen Aerogels to post earnings of ($0.01) per share and revenue of $73.4150 million for the quarter. Aspen Aerogels has set its FY 2025 guidance at -3.860–3.730 EPS.Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings results on Thursday, August 7th. The construction company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. Aspen Aerogels had a positive return on equity of 2.92% and a negative net margin of 78.53%.The firm had revenue of $78.02 million during the quarter, compared to analysts’ expectations of $72.53 million. During the same quarter in the previous year, the business earned $0.21 earnings per share. The company’s revenue was down 33.8% on a year-over-year basis. On average, analysts expect Aspen Aerogels to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aspen Aerogels Stock Down 5.3%

ASPN stock opened at $7.71 on Tuesday. Aspen Aerogels has a 1-year low of $4.16 and a 1-year high of $18.95. The business has a fifty day moving average price of $7.40 and a 200-day moving average price of $6.77. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.98 and a quick ratio of 3.31. The stock has a market capitalization of $635.16 million, a P/E ratio of -2.02 and a beta of 2.80.

Insider Buying and Selling

In related news, CAO Santhosh P. Daniel sold 4,410 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.31, for a total transaction of $32,237.10. Following the completion of the sale, the chief accounting officer owned 19,879 shares in the company, valued at approximately $145,315.49. This represents a 18.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Aspen Aerogels

A number of hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its position in Aspen Aerogels by 89.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,274,356 shares of the construction company’s stock valued at $8,143,000 after acquiring an additional 602,586 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Aspen Aerogels by 105.4% during the second quarter. JPMorgan Chase & Co. now owns 1,246,506 shares of the construction company’s stock valued at $7,379,000 after purchasing an additional 639,753 shares during the period. Invesco Ltd. grew its holdings in Aspen Aerogels by 1,045.5% during the second quarter. Invesco Ltd. now owns 831,991 shares of the construction company’s stock valued at $4,925,000 after purchasing an additional 759,360 shares during the period. Bank of America Corp DE grew its holdings in Aspen Aerogels by 124.2% during the second quarter. Bank of America Corp DE now owns 818,212 shares of the construction company’s stock valued at $4,844,000 after purchasing an additional 453,221 shares during the period. Finally, HRT Financial LP grew its holdings in Aspen Aerogels by 668.7% during the second quarter. HRT Financial LP now owns 595,742 shares of the construction company’s stock valued at $3,526,000 after purchasing an additional 518,243 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Aspen Aerogels in a research note on Wednesday, October 8th. Canaccord Genuity Group decreased their price target on Aspen Aerogels from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Barclays cut Aspen Aerogels from an “equal weight” rating to an “underweight” rating and boosted their price target for the stock from $7.00 to $16.00 in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.50.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.